Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Completed · Phase 2 · Has a placebo group

Conditions studied: Intermittent Claudication, Peripheral Artery Disease

In brief

The objective of the study is to establish the safety profile of Intramuscular PLX-PAD injections and to evaluate the clinical efficacy of it in IC subjects comprising of 4 treatment groups: 1. Double treatment of PLX-PAD low dose 2. Double treatment of PLX-PAD high dose 3. Double treatment of Placebo 4. Single treatment of PLX-PAD high dose and additional treatment of Placebo. Subjects will receive the assigned treatment twice to the affected leg, within 12-weeks interval between each treatment. The study will be comprised of 5 stages: Screening period of up to 4 weeks,first treatment of PLX-PAD or placebo followed by additional injection after 12 weeks and with follow-up of 12 months post second injection

Key facts

Study ID

NCT01679990

Run by

Pluristem Ltd.

People needed

180

Starts

2012-11-05

Expected to finish

2019-02-09

Last updated by the study team

2019-02-12

Who can join

Age: 45 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male or female subjects between 45 to 85 years of age (inclusive) at the time of screening visit.
• Subjects with a diagnosis of peripheral artery disease, secondary to atherosclerosis, confirmed by one of the following criteria assessed at the screening visit:
• Resting ankle-brachial index (ABI) ≤ 0.80 or
• Resting ABI ≤ 0.90 and >20% decrease in ABI from rest to exercise when measured within 1 minute after treadmill exercise or
• Toe-brachial index (TBI) ≤ 0.60
• Lifestyle-limiting, moderate to severe claudication (symptoms present and stable for > 6 months and not significantly changed within the past 3 months prior to screening).
• Evidence of significant (>50%) stenosis infra-inguinal occlusive disease as confirmed by documented results from Duplex, MRA, CTA and/or contrast angiogram completed within 3 months prior to screening.
• The longest maximal walking distance (MWD) from the Screening Period exercise treadmill tests (ETT), utilizing a modified Gardner Protocol (Appendix I), must be between 1 and 10 minutes (inclusive).
• Subjects who have persistent claudication symptoms despite having been recommended an exercise program if feasible, and or despite having been on a stable dose of Cilostazol, if indicated. Subjects should be Cilostazol free for at least 2 weeks prior to the first ETT.
• Subjects should be receiving standard of care drugs for vascular disease including anti-platelet agent(s) and statin medication, as well as anti-hypertensive medication(s) and oral hypoglycemic agents/insulin, if indicated.
• Signed written informed consent.

You may not qualify if…

• Ischemic rest pain; ulceration or gangrene (Fontaine class III-IV; Rutherford category 4-6).
• Failed lower extremity arterial reconstruction (surgical or endovascular) or sympathectomy within the prior one month of screening.
• Planned revascularization (surgical or endovascular intervention) within 12 months after screening.
• Lower extremity arteries inflow obstruction (defined as a greater than 50% stenosis of aorta, iliac and/or common femoral arteries).
• History of Buerger's disease.
• Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or systolic blood pressure > 180 mmHg during screening).
• Uncontrolled diabetes defined as glucose control HbA1c > 9% at screening.
• Life-threatening ventricular arrhythmia - except in subjects with an implantable cardiac-defibrillator.
• Serum Creatinine level>2.5mg/dl.
• SGPT (ALT), SGOT (AST) >2.5 x upper limit of normal range.
• Hemoglobin < 10 g/dl.
• Unstable cardiovascular disease defined as myocardial infarction (STEMI or NSTEMI) within 3 months prior to screening, or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged episodes.
• Transient Ischemic Attack (TIA)/Stroke within 3 months prior to screening.
• Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage III to IV).
• Subjects with Implant of mechanical prosthetic heart valve(s).
• Pulmonary disease requiring supplemental oxygen treatment on a daily basis.
• Severe, active infection of the involved extremity(ies), including osteomyelitis, fasciitis, or severe/purulent cellulitis.
• History of malignancy within 5 years prior screening requiring chemotherapy and/or radiotherapy and/or immunotherapy, excluding basal or squamous cell carcinoma of the skin.
• Exercise is limited by any condition other than IC, including but not limited to congestive heart failure, chronic pulmonary disease, angina pectoris, or degenerative joint disease.
• Uninterrupted use of warfarin or non-steroidal anti-inflammatory agents (with the exception of ibuprofen at doses up to 1,200 mg/day or Diclofenac at dose of 75mg/day).
• Subjects who are on oral anticoagulant therapy (warfarin, dabigatran, apixaban, endoxaban and rivaroxaban). Unless, upon primary care physician and/or Investigator's discretion the subjects who are on warfarin treatment can switch to Low Molecular Weight Heparin treatment (such as: Clexane) 5-7 days prior study treatment administration and return to warfarin treatment 24 hours post study treatment administration.
• Subjects who are taking immunosuppressive treatment (including high dose steroids).
• Known allergies to protein products (Bovine serum, or recombinant trypsin) used in the cell production process.
• Known sensitivity to Gentamycin.
• Known sensitivity to antihistamine drugs.

Where it is running

• Cardiology, P. C. and Center for Therapeutic Angiogenesis — Birmingham, Alabama, United States
• Tampa Bay Medical Research — Clearwater, Florida, United States
• Florida Researc Network, LLC — Gainesville, Florida, United States
• DMI Research — Pinellas Park, Florida, United States
• Dr. Nadarajah Janaki — Evans, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• University of Kentucky Research Foundation — Lexington, Kentucky, United States
• Cardiovascular Division, MMC, University of Minnesota — Minneapolis, Minnesota, United States
• Cardiovascular Institute, Mount Sinai School of Medicine — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Dr. Mohler Emile — Philadelphia, Pennsylvania, United States
• Omega Medical Center — Warwick, Rhode Island, United States
• Turkey Creek Medical Center — Knoxville, Tennessee, United States
• Clinical Trials of Texas — San Antonio, Texas, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Universtiäts-Herzzentrum Freiburg und Bad-Krozingen — Bad Krozingen, Germany
• Franziskus-Krankenhaus — Berlin, Germany
• Universitätsklinikum Carl Gustav Carus — Dresden, Germany
• ASKLEPIOS Klinik St. Georg — Hamburg, Germany
• Universitätsklinik Heidelberg — Heidelberg, Germany
• Universitätsklinikum Jena — Jena, Germany
• SRH Klinikum Karlsbad-Langensteinbach — Karlsbad, Germany
• Universitätsmedizin der Johannes Gutenberg-Universität Mainz — Mainz, Germany
• Universitätsklinikum Münster — Münster, Germany
• "Mor" Instituite, Horev M.C — Haifa, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.